O
OriCell Therapeutics
Aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for…
About OriCell Therapeutics
OriCell Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of cell therapies for cancer treatment. The company has established a proprietary technology platform, OriCAR, which is designed to enhance the effectiveness of Chimeric Antigen Receptor T-cell (CAR-T) therapies.
Their primary focus is on addressing unmet medical needs in oncology, particularly for solid tumors and hematological malignancies. OriCell's pipeline includes several investigational CAR-T therapies. One of their leading candidates, OriCAR-017, targets GPRC5D for the treatment of relapsed and refractory multiple myeloma. This therapy has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), indicating its potential to address a serious condition.
The company operates internationally, with a presence in both China and the United States, allowing it to conduct clinical trials and navigate regulatory processes in multiple key markets. OriCell's business model is centered on the research and development of these advanced therapies, with the ultimate goal of commercializing them to provide new treatment options for cancer patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- China
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 73.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Woman Founder, T Cell, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2026 | $110M | $600M | E-Town Capital · NGS Super · Elikon Venture · Lucion Group | ↗ |
| SERIES COther financing | Jan 2026 | $70M | $600M | Elikon Venture · E-Town Capital · NGS Super · Qiming Venture Partners | ↗ |
Growth signals
Latest recorded traffic for OriCell Therapeutics is 1.7K monthly website visits, down 10.5% over the last three months. OriCell Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A11 investors entered at this stage
Xiamen C&D- ZIZhangjiang Science and Technology Investment
Yijing Capital
Quan Capital- CCC&D Emerging Capital
- SFSuzhou Fund
- BMBoquan Equity Investment Management
- SVShanghai Sci-Tech VC
- JCJ-one Capital
Qatar Investment Authority
RTW Investments
Series B and later8 investors entered at this stage
- EVElikon Venture
E-Town Capital
NGS Super
Vivo Capital- SMShunxi Private Equity Fund Management
Lucion Group
Talon Capital Corp
Talon Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OriCell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OriCell Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.